Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Prognostic utility of cell-free hydroxymethylation in small cell lung cancer
EF 2022-23
Résumé
Small-cell lung cancer (SCLC) is an aggressive disease that develops and spreads rapidly. Although most SCLC patients respond well to chemotherapy initially, many of their tumours grow back, therefore only 1-5% of SCLC patients will survive past 5 years. SCLC tumours tend to have TP53 and RB1 mutations, however these mutations are hard to target, therefore it is difficult to develop targeted therapies for SCLC. Recently, studies have revealed that 5-hydroxymethylcytosine (5hmC), which is a change to the surface of DNA that doesn't alter the DNA sequence, can regulate gene expression and promote cancer progression. Multiple cancer studies have shown that low 5hmC expression levels are related to worse survival and cancer growth. However, it is unclear how 5hmC affects SCLC and whether changes in 5hmC expression levels will affect SCLC development. Additionally, a major challenge in studying SCLC is that tumour tissue samples are difficult to obtain. In our project, we aim to address these gaps by detecting 5hmC expression levels in cell-free DNA (cfDNA) found in the blood of SCLC patients.
To identify key 5hmC signatures in the cfDNA of SCLC patients, we will examine the whole genome of hydroxymethylated regions using the hMe-Seal assay. Differences in 5hmC expression between cancerous and non-cancerous individuals will be analyzed using machine learning. We will also explore changes in 5hmC expression before and after cancer recurrence and use a special CRISPR system to alter these 5hmC-specific genes in SCLC cell lines to determine changes in cancer growth.
Ultimately, our study will improve the understanding of how 5hmC expression and changes contribute to SCLC lethality and relapse, thus offering potential targetable biomarkers for treating this deadly disease.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486017
Name
Li Janice
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Prognostic utility of cell-free hydroxymethylation in small cell lung cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
5-Hmc-Seal; Cell-Free Dna; Crispr; Disease Relapse; Epigenetic Biomarker; Hydroxymethylcytosine; Liquid Biopsy; Prognosis; Small Cell Lung Cancer
Abstract
Small-cell lung cancer (SCLC) is an aggressive disease that develops and spreads rapidly. Although most SCLC patients respond well to chemotherapy initially, many of their tumours grow back, therefore only 1-5% of SCLC patients will survive past 5 years. SCLC tumours tend to have TP53 and RB1 mutations, however these mutations are hard to target, therefore it is difficult to develop targeted therapies for SCLC. Recently, studies have revealed that 5-hydroxymethylcytosine (5hmC), which is a change to the surface of DNA that doesn't alter the DNA sequence, can regulate gene expression and promote cancer progression. Multiple cancer studies have shown that low 5hmC expression levels are related to worse survival and cancer growth. However, it is unclear how 5hmC affects SCLC and whether changes in 5hmC expression levels will affect SCLC development. Additionally, a major challenge in studying SCLC is that tumour tissue samples are difficult to obtain. In our project, we aim to address these gaps by detecting 5hmC expression levels in cell-free DNA (cfDNA) found in the blood of SCLC patients.
To identify key 5hmC signatures in the cfDNA of SCLC patients, we will examine the whole genome of hydroxymethylated regions using the hMe-Seal assay. Differences in 5hmC expression between cancerous and non-cancerous individuals will be analyzed using machine learning. We will also explore changes in 5hmC expression before and after cancer recurrence and use a special CRISPR system to alter these 5hmC-specific genes in SCLC cell lines to determine changes in cancer growth.
Ultimately, our study will improve the understanding of how 5hmC expression and changes contribute to SCLC lethality and relapse, thus offering potential targetable biomarkers for treating this deadly disease.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Li, Janice
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~